Is There Any Evidence of Monocytes Involvement in Alzheimer's Disease? A Pilot Study on Human Postmortem Brain

Camelia-Maria Monoranu1, Tim Hartmann1, Sabrina Strobel2

  • 1Institute of Pathology, Department of Neuropathology, Julius-Maximilian-University of Wuerzburg, Wuerzburg, Germany.

Abstract

Insights

In Alzheimer's disease (AD), few C-C chemokine receptor type 2 (CCR2)-positive monocytes infiltrate the human brain. Early microglial reactions, not monocyte infiltration, are linked to AD pathology in vulnerable brain regions.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Neuroinflammation is increasingly implicated in neurodegenerative diseases like Alzheimer's disease (AD).
  • While microglial activation is well-documented in AD, the role of monocytes remains less understood.
  • Animal models suggest monocyte infiltration aids amyloid-β clearance, but this is not confirmed in human postmortem brains.

Purpose of the Study:

  • To investigate the distribution of microglial subtypes (CD68, HLA-DR, CD163, CD206) in AD.
  • To determine the involvement of C-C chemokine receptor type 2 (CCR2)-positive monocytes in AD pathogenesis.
  • To compare monocyte infiltration in human AD brains with findings from AD animal models.

Main Methods:

  • Utilized formalin-fixed, paraffin-embedded brain tissue from four vulnerable regions (hippocampus, occipital lobe, brainstem, cerebellum) of AD patients across Braak stages.
  • Included age-matched control subjects for comparison.
  • Employed immunostaining techniques to identify microglial markers and CCR2-positive cells.

Main Results:

  • Only rare CCR2-positive cells were detected across all brain regions and AD stages.
  • The brainstem and hippocampus showed the highest numbers of these cells.
  • Monocyte recruitment appears inefficient in aged human brains, with significantly reduced or absent infiltration.

Conclusions:

  • Contrary to animal studies, human AD brains exhibit limited myeloid monocyte association with pathology.
  • Early microglial activation, particularly by pro-inflammatory subtypes, correlates with early AD changes in vulnerable brain areas.
  • The findings suggest a limited role for monocyte infiltration in human AD, emphasizing early microglial responses.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...